Aude S. Peden

USPTO Publishes Drug Patent And Exclusivity Study Report

Exception To The Rule? Late Submission Of Evidence As Supplemental Information Under 37 C.F.R. 42.123(b)

Coronavirus Innovation Guideposts On The Eve Of The COVID-19 Pandemic

PTAB Strict On Motivation Evidence For Obviousness